umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE study
Department of Cardiology and Department of Nephrology, Oslo University Hospital, Norway.
Department of Cardiology and Department of Nephrology, Oslo University Hospital, Norway.
Department of Cardiology and Department of Nephrology, Oslo University Hospital, Norway.
Department of Cardiology and Department of Nephrology, Oslo University Hospital, Norway. (Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA)
Show others and affiliations
2010 (English)In: American Journal of Hypertension, ISSN 0895-7061, Vol. 23, no 8, 845-851 p.Article in journal (Refereed) Published
Abstract [en]

Background

It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH). The aim of the present investigation was to test the hypothesis that SUA predicts development of NOD in these patients.

Methods

In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a double-masked, parallel-group design, 9,193 patients with hypertension and electrocardiographic LVH were randomized to losartan- or atenolol-based antihypertensive treatment and followed for a mean of 4.9 years. At baseline, 7,489 patients with available SUA measurements did not have diabetes mellitus and were thus at risk of its development during the study. We used Cox regression analyses to investigate whether SUA predicted development of NOD.

Results

NOD developed in 522 of 7,489 patients. The association between baseline SUA and development of NOD was significant (hazard ratio (HR) 1.29 per s.d. (1.3 mg/dl), 95% confidence interval (CI) 1.18–1.42, P < 0.001) after adjustment for treatment with losartan vs. atenolol, baseline serum glucose, urinary albumin/creatinine ratio, estimated glomerular filtration rate and Framingham risk score, time-varying systolic and diastolic blood pressure, and time-varying LVH by Cornell voltage-duration product and Sokolow–Lyon voltage. In parallel analyses, baseline quartiles of SUA were significantly associated with increasing NOD (HR 1.28, 95% CI 1.18–1.40, P < 0.001). Time-varying SUA was also associated with NOD (HR 1.10 per s.d. [1.3 mg/dl], 95% CI 1.02–1.19, P = 0.015).

Conclusion

Our analysis suggests that SUA is an independent risk marker for NOD in hypertensive patients with LVH.

Place, publisher, year, edition, pages
Nature Publishing Group, 2010. Vol. 23, no 8, 845-851 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:umu:diva-42086DOI: 10.1038/ajh.2010.89PubMedID: 20431530OAI: oai:DiVA.org:umu-42086DiVA: diva2:408514
Conference
Conference Information: 19th European Meeting on Hypertension Jun 12-16 2009Milan, Italy
Available from: 2011-04-05 Created: 2011-04-05 Last updated: 2012-09-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindholm, Lars H
By organisation
Family Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 70 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf